30-Second Takeaway
- 2024–2025 monovalent COVID-19 vaccines still cut JN.1-lineage hospitalizations and markedly reduce invasive ventilation or death.
- Viable M. tuberculosis infection affects a smaller fraction of humanity than TST/IGRA positivity suggests, with recent infection highly concentrated geographically.
- Enterococcal bacteremia and vancomycin-resistant E. faecium continue to rise, demanding tighter infection control and empiric coverage vigilance.
- Ultra-rapid phenotypic AST from primary specimens could compress time-to-targeted therapy from days to under an hour.
- Genomic and colonization data show MDR-TB and ESCrE are largely local-transmission problems, enabling more focused containment strategies.
Week ending February 7, 2026
Severe infections, AMR, and vaccines: near-term implications for ID practice
2024–2025 COVID-19 vaccine meaningfully protects against JN.1-lineage severe disease
Among 8,493 hospitalized adults at 26 US hospitals, 2024–2025 COVID-19 vaccination reduced JN.1-lineage–associated hospitalizations and severe outcomes. Vaccine effectiveness against COVID-19–associated hospitalization was 40% (95% CI, 27%–51%), with protection sustained through 90–179 days post-vaccination. Effectiveness against invasive mechanical ventilation or death was 79% (95% CI, 55%–92%), indicating strong protection from the worst outcomes. Effectiveness against hospitalization varied by lineage: 49% for KP.3.1.1, 34% for XEC, and 24% for LP.8.1, with longer time-since-dose for later lineages.
Modeling suggests a smaller, high-risk pool of viable M. tuberculosis infection
A deterministic country-level model estimated that in 2022 about 288.9 million people (3.7% globally) harbored viable M. tuberculosis infection. Recent infection within two years was estimated in 133.7 million people (1.7% of the global population), who have the greatest progression risk. Nearly half of recent infections occurred in the WHO South-East Asia region, with India, Indonesia, and China bearing the largest national burdens. Children under 15 years accounted for 12% of recent infections, emphasizing pediatric preventive-therapy needs in high-burden settings.
Enterococcal bacteremia incidence and vancomycin-resistant E. faecium remain high in Victoria
Over 35 years in Victoria, Australia, 11,157 enterococcal bacteremia episodes were reported, mainly Enterococcus faecalis and Enterococcus faecium. Population incidence increased from under 3 per 100,000 in 1988 to over 10 per 100,000 by 2022, after adjusting for reporting variability. Hospital incidence rose from 2.8 to 4 episodes per 10,000 admissions between 2011 and 2022, signaling growing healthcare-associated burden. While E. faecalis remained largely susceptible, E. faecium exhibited persistently high vancomycin resistance of about 51%–67% over the last decade.
QolorPhAST delivers phenotypic AST directly from specimens in under an hour
QolorPhAST is a modular microfluidic nanoplasmonic platform enabling parallel bacterial identification and phenotypic AST directly from clinical specimens. It reduces drug susceptibility profiling times from days to minutes by bypassing overnight cultures and pathogen isolation. Across 10 bacterial species and 34 strains, it multiplexed species identification and MIC determination across antibiotic concentrations. In a proof-of-concept UTI cohort, QolorPhAST achieved 100% species-identification accuracy, 91.81% average categorical agreement, and 86.4% average essential agreement, with 36-minute turnaround.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.